MaxCyte, Inc. (MXCT) vs Spruce Biosciences, Inc. (SPRB)
A side-by-side comparison of MaxCyte, Inc. and Spruce Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MXCT
MaxCyte, Inc.
$1.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SPRB
Spruce Biosciences, Inc.
$42.79HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — MXCT vs SPRB
growth of $100 · dividends reinvested · last 5yMXCT -93.6% (-42.4%/yr)SPRB -93.4% (-42.0%/yr)SPRB compounded faster over this window
MXCT SPRB
MXCT vs SPRB: by the numbers
- •SPRB is the larger company ($118M vs $117M market cap).
- •Both run net losses; SPRB's is the smaller (0.00% vs -114.77% net margin).
Metrics side by side
Valuation
| Metric | MXCT | SPRB |
|---|---|---|
| P/S ratio | 3.76 | N/A |
| P/B ratio | 0.74 | 1.41 |
Profitability
| Metric | MXCT | SPRB |
|---|---|---|
| Gross margin | 79.43% | 0.00% |
| Operating margin | -137.12% | 0.00% |
| Net margin | -114.77% | 0.00% |
| ROE | -22.45% | -61.33% |
| ROIC | -19.83% | -50.67% |
Growth (annualized)
| Metric | MXCT | SPRB |
|---|---|---|
| Revenue CAGR (5Y) | 1.46% | N/A |
| Total return CAGR (5Y) | -37.32% | -36.23% |
Frequently asked
- How have MXCT and SPRB total returns compared?
- Over the past 5 years, MXCT delivered -37.32% and SPRB delivered -36.23% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.